Groupe d'Etude en Oncologie du Quebec

Title	Health Related Quality of Life (HRQL) and Symptom Assessment in Patients Diagnosed With Diffuse Intrinsic Pontine Glioma (DIPG) or Recurrent and Re-irradiated Brain Tumours and Their Caregivers: A Non-Therapeutic Study
Protocole ID	DIPG HRQOL
ClinicalTrials.gov ID	NCT04670016
Cancer Type(s)	Pediatric
Phase	Other
Stage
Study Type	Other
Drug
Institution	CHU DE QUEBEC – UNIVERSITE LAVAL CHUL ET CENTRE MERE-ENFANT SOLEIL 2705 boulevard Laurier, Québec, QC, G1V 4G2
City
Principal Investigator	Dr. Valérie Larouche
Coordinator	Panagiota Giannakouros 418-525-4444 poste 40121
Status	Recruiting
Activation Date
Eligibility Criteria	Patient aged >2 and <21 years treated with a repeat course of radiation for DIPG or other recurrent or progressive brain tumour. Radiation for the first tumour must be a primary brain neoplasm (i.e. not leukemia). Enrollment within 14 days of starting re-irradiation (RT2). Patients with malignant transformation of the first tumour are eligible. There are no restrictions on histology or RT1/RT2 dose-fractionation or RT2 body site. In other words, RT2 may be directed at a different location to RT1. The patient is treated at a site where the study is approved by the local ethics board Consent, and, if applicable, assent, has been obtained according to institutional standards
Exclusion Criteria	Inability to complete questionnaires in English or French.

Groupe d'étude en oncologie du Québec